AR and prostate carcinoma: An amplification loop may exist, as AR- cancers cells express high levels of IL-1β, while AR+ cells do not and androgen-deprivation drugs, that is, leuprolide and bicalutamide, inhibit prostate cancer cells’ mediated IL-1β secretion by peripheral blood mononuclear cells (PBMC) in vitro [105,106].